Actively Recruiting
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Led by Fudan University · Updated on 2025-04-06
104
Participants Needed
1
Research Sites
287 weeks
Total Duration
On this page
Sponsors
F
Fudan University
Lead Sponsor
P
Peking Union Medical College Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.
CONDITIONS
Official Title
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Confirmed diagnosis of early-stage endometrial cancer (endometrioid, grade I, without myometrial invasion) by biopsy, curettage, or hysteroscopy
- No signs of suspicious myometrial invasion or spread outside the uterus by MRI, CT, or transvaginal ultrasound
- Strong desire to preserve fertility or keep the uterus
- Good compliance and willingness to follow up at Obstetrics and Gynecology Hospital of Fudan University on time
You will not qualify if you...
- Endometrial cancer with suspicious myometrial invasion or spread outside the uterus
- Recurrent endometrial cancer
- Severe medical diseases or severely impaired liver or kidney function
- Other types of endometrial cancer or malignant reproductive system tumors; breast cancer or other hormone-dependent tumors where progesterone cannot be used
- Need for hysterectomy or treatments other than drug therapy
- Known or suspected pregnancy
- Contraindications to Medroxyprogesterone Acetate, Megestrol Acetate, Triprorelin Acetate, Letrozole, or pregnancy
- Hormone treatment within 3 months before the trial
- Acute severe diseases such as stroke, heart attack, or history of thrombosis
- Smoking more than 15 cigarettes per day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Obstetrics and Gynecology Hospital, Fudan University
Shanghai, China, 200011
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here